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EXPERT OPINION
Abstract: Dopaminergic agents, anticonvulsants, benzodiazepines, opiates, and iron
supplementation comprise the classes of medications commonly used to treat restless legs
syndrome (RLS), which is a disorder that is estimated to affect about 1 in 10 individuals
worldwide and impacts an affected patient’s sleep, mood, daytime function, and quality of
life. RLS is characterized by an urge to move the legs that is worse at bedtime and at rest; the
symptoms are temporarily relieved by leg movement. It is frequently accompanied by periodic
limb movements during sleep (PLMS), which may independently disrupt sleep and may cause
daytime drowsiness. Dopaminergic agents are considered to be first-line therapy in the
management of RLS as well as PLMS. Ropinirole (Requip®, GlaxoSmithKline) is a dopamine
agonist that was the first medication approved by the US Food and Drug Administration
(FDA) for the treatment of moderate-to-severe primary RLS. Based on several large-scale
clinical trials and open-label clinical series, this medication has been demonstrated to be
effective and safe in treating the motor symptoms of RLS and improving sleep quality.
Keywords: ropinirole, restless legs syndrome, RLS, periodic limb movements
Restless legs syndrome
Restless legs syndrome (RLS) is a common neurologic disorder that is largely under-
diagnosed and under-treated. RLS is characterized by an urge to move the legs that
is worse at rest and at bedtime. The urge to move often presents as leg discomfort,
but may range from mild irritation to disruptive, painful sensations. The symptoms
typically occur near bedtime but may be present throughout the day in severe cases.
Patients with RLS obtain symptom relief with movement, although the relief is
temporary with rapid return of symptoms. RLS is present in childhood through old
age. It is a chronic condition, but it may present with a relapsing-remitting course
characterized by periods of remission that last weeks to sometimes years. RLS is
typically and frequently associated with disturbed sleep, in which the patient
experiences a delay in the onset of sleep and/or difficulty maintaining sleep. The
latter is often characterized by fragmented sleep resulting from an inability to rapidly
fall back asleep after awakenings throughout the night. The RLS morbidities of
decreased functional alertness and emotional distress appear to be mostly secondary
to the sleep disturbance associated with RLS (Kushida et al 2004). Other morbidities
associated with RLS include disruption of bed-partner’s sleep and increased risk of
work-related or motor-vehicle accidents due to daytime fatigue or sleepiness.
Prevalence
The overall prevalence of RLS is estimated to be 10%. It appears to be more common
in populations of Northern and Western European extraction, and less common in
Asian (Kageyama et al 2000; Tan et al 2001) and Southern European (Turkey)
populations (Sevim et al 2003). An early study using a population sample from
Kentucky, US found that 10% of respondents experienced RLS symptoms 5 or more
nights per month (Phillips et al 2000). The multinational RLS Epidemiology,
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Symptoms, and Treatment (REST) Primary Care Study
found that 9.6% of patients reported experiencing symptoms
at least weekly and 88.4% of RLS sufferers reported at least
one sleep-related symptom (Hening et al 2004a).
Interestingly, in this latter study, although 64.8% reported
consulting a physician about their symptoms, only 12.9%
reported receiving a diagnosis of RLS. The prevalence of
RLS increases with age; however, the prevalence of RLS in
children and the elderly has not been systematically
investigated.
Phenotypes and genotypes
RLS can be divided into a more common, idiopathic,
primary form and secondary forms associated with iron
deficiency, pregnancy, and renal failure. The primary form
of RLS appears to have a familial preponderance but with
the exception of a monozygotic twin study that indicated
concordance for RLS symptoms (Ondo et al 2000) and the
identification of possible chromosomal loci at 12q, 14q, and
9p (Desautels et al 2001; Bonati et al 2003; Winkelmann et
al 2006), the genetics of RLS remain unclear and it is
considered to be a complex, heterogenetic disorder. In
addition, early- and late-onset (over age 45) RLS has been
described, with early-onset RLS occurring more commonly
in families, progressing slower with age, and possessing a
more limited relation to serum iron status compared to late-
onset RLS (Allen and Earley 2000).
Etiology
The cause of RLS is unknown, but a defect in the dopamine-
iron stores/transport mechanism is strongly suspected and
a mechanism to explain the connection between iron
deficiency and dopamine dysfunction in RLS has been
proposed (Earley et al 2000a). Although not all imaging
studies have found dopamine abnormalities (Eisensehr et
al 2001), a mild reduction of dopamine function in the
striatum region of the brain was detected by imaging studies
using ligands targeted to pre- and post-synaptic dopamine
sites (Turjanski et al 1999; Ruottinen et al 2000). Iron is a
cofactor for the hydroxylation of tyrosine hydroxylase, the
rate-limiting enzyme in dopamine synthesis, and iron
deficiency is frequently found in the major secondary forms
of RLS (anemia, pregnancy, renal failure). RLS symptoms
are associated with low iron stores (serum ferritin <50 mcg/
L) (Sun et al 1998), and these symptoms are improved with
subsequent iron supplementation. Additionally, studies
examining cerebrospinal fluid (Earley et al 2000b), magnetic
resonance imaging (MRI) (Allen et al 2001), and brains at
autopsy (Connor et al 2003) have shown low iron levels in
patients with primary RLS. Long-term dopaminergic
treatment has been observed to reduce hyperalgesia in RLS
patients, prompting a theory that implicates disturbed
supraspinal pain modulation involving
 the basal ganglia and/
or descending dopaminergic pathways in RLS
pathophysiology (Stiasny-Kolster et al 2004). However, pain
processing includes a complex, reciprocal interaction
between dopaminergic and opioidergic systems, the
mechanisms of which are not completely understood.
Diagnosis
Four essential diagnostic features of RLS were developed
through a consensus conference at the National Institutes
of Health in 2002 in conjunction with the International
Restless Legs Syndrome Study Group (IRLSSG) (Allen et
al 2003):
(1)  A strong urge to move the legs, usually
associated with uncomfortable sensations in the
legs.
These sensations may be characterized by patients as vague,
indescribable sensations to “creepy-crawly” feelings to
irritating, painful symptoms. Sometimes the patient is unable
to describe the symptom of leg discomfort and simply says
that he or she has an urge or need to move the legs. These
sensations are rarely found in the arms and trunk.
(2) Symptoms that start or become worse with
rest.
Periods of recumbency, sitting, and rest, or situations in
which leg movement is restricted can initiate or exacerbate
RLS. For example, theater or airplane seats can be almost
unbearable for a patient with severe RLS.
(3)  A temporary or partial relief of symptoms
with movement, such as stretching or walking.
Almost immediate alleviation of symptoms typically occurs
with movement. However, this relief typically lasts only a
few seconds to a few minutes, and prompts the RLS sufferer
to repetitively flex and extend his or her legs or walk for
short periods of time.
(4)  A worsening of symptoms in the evening or at
night.
RLS does have a circadian component; the symptoms
frequently worsen as bedtime approaches.
Tools that can assist the clinician in the diagnosis include
those for screening (Restless Legs Syndrome QuestionnaireNeuropsychiatric Disease and Treatment 2006:2(4) 409
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[RLSQ]) (Allen and Earley 2001), severity assessment
(International RLS [IRLS] Rating Scale (Walters et al
2003)), subjective sleep assessment (sleep logs or diaries),
quality of life assessment (Atkinson et al 2004; Abetz et al
2005), and objective provocation/validation (suggested
immobilization test [SIT] (Montplaisir et al 1998)). Ancillary
testing is not necessary to establish the diagnosis of RLS,
except in situations where secondary RLS (eg, ferritin and
transferrin levels for iron deficiency, BUN and creatinine
for renal failure) is suspected or when other possible
disorders need to be excluded. These latter disorders include
leg cramps and neuropathies, which can mimic RLS by
sharing similar symptoms. Leg cramps may be differentiated
from RLS in that the cramps typically affect specific muscle
groups (eg, gastrocnemius), may be unilateral, can be
associated with strenuous exercise and electrolyte
imbalance, and may not temporarily be relieved by leg
movement. Neuropathies are typically associated with
medical conditions such as diabetes or back injury and do
not have a circadian rhythmicity nor are relieved by leg
movement. Further testing (eg, folate, B12, glycosylated
hemoglobin, electromyography/nerve conduction velocity
studies) may help to identify specific causes of neuropathies.
Other disorders on the differential diagnosis include
akathisia, vasculopathies, myelopathies, muscular pain-
fasciculation syndromes, anxiety disorders, nocturnal
epilepsy, rhythmic movement disorder, attention deficit-
hyperactivity disorder, sleep starts, nocturnal paroxysmal
dystonia, erythromelalgia, and myokymia.
Polysomnography (sleep study) is generally not indicated
in the evaluation of RLS unless periodic limb movement
disorder or an RLS-associated sleep disorder is suspected.
RLS patients frequently have periodic limb movements
(PLMs), characterized as stereotyped movements of the legs,
typically big toe extension, ankle dorsiflexion, knee flexion,
and hip flexion that occur on a repetitive basis during sleep
(PLMS) or wake (PLMW) and can be present in all limbs
though are most common in the legs. The current
polysomnographic criteria for scoring PLMS consist of
movements that are 0.5–5 seconds in duration, separated
by 5–90 seconds, and are greater than 25% of toe
dorsiflexion during calibration (The Atlas Task Force 1993;
American Academy of Sleep Medicine 2005). A train of
four of these movements that meet these criteria must be
present in order for any of them to be counted as periodic
limb movements. PLMS may be associated with arousals
or awakenings from sleep, and it is suspected that these
disturbances result in sleep fragmentation, which in turn
may lead to daytime fatigue and sleepiness. However, this
is controversial since the number of PLMS do not correlate
with the level of daytime sleepiness (Montplaisir et al 1998).
Nevertheless, PLMS greater than 15 per hour plus a clinical
sleep disturbance or a complaint of daytime fatigue is
diagnostic for periodic limb movement disorder (PLMD)
in adults (American Academy of Sleep Medicine 2005). This
is also not without controversy; since approximately 80%
of individuals with RLS report significant PLMS
(Montplaisir et al 1997), there is the belief that RLS and
PLMD may not be distinct and separate entities, but rather
comprise the same neurologic disease state.
Current therapies
RLS and PLMD are optimally treated with pharmacologic
intervention; non-pharmacologic therapy such as exercise,
warm baths, thermal biofeedback, leg vibration/massage,
and acupuncture have had mixed success in limited studies
(Kuo and Kushida 2003). However, the implementation of
good sleep hygiene practices may be helpful as an adjunct
to pharmacologic treatment (Table 1), as well as the
management of concomitant conditions such as a peripheral
neuropathy or vasculopathy. The primary pharmacologic
treatment of RLS consists of dopaminergic agents,
anticonvulsants, benzodiazepines, opiates, and iron
supplementation. Of these classes of medications,
dopaminergic agents have been the subject of the most recent
and extensive investigation (Chesson et al 1999; Hening et
al 1999, 2004b; Littner et al 2004). Dopamine agonists, in
particular, are among the best-studied medications for RLS
and are considered to be first-line therapy in the management
of RLS.
Ropinirole
Ropinirole (Requip
®, GlaxoSmithKline) is a non-ergoline
dopamine agonist that was the first medication approved
(May 4, 2005) by the US Food and Drug Administration
(FDA) for the treatment of moderate-to-severe RLS.
Chemistry
The IUPAC chemical name of ropinirole hydrochloride is
4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one, and it is
the hydrochloride salt of 4-[2-(dipropylamino)ethyl]-1,3-
dihydro-2H-indol-2-one monohydrochloride. It has an
empirical formula of C16H24N2O·HCl and its molecular
weight is 296.84 (260.38 as the free base).Neuropsychiatric Disease and Treatment 2006:2(4) 410
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Pharmacokinetics and metabolism
The majority of the following data were derived from the
Internet-based version of the Physicians’ Desk Reference
(Thomason Healthcare 2005). Ropinirole is a non-ergoline
derivative with high relative in vitro specificity and full
intrinsic activity at the D2 and D3 dopamine receptor
subtypes, and it binds with higher affinity to D3 compared
with D2 or D4 receptor subtypes. It has moderate in vitro
affinity for opioid receptors. Ropinirole and its metabolites
have negligible in vitro affinity for dopamine D1, 5HT1,
5HT2, benzodiazepine, GABA, muscarinic, and alpha1-,
alpha2-, or beta-adrenoreceptors. Ropinirole is rapidly
absorbed after oral administration, and it reaches peak
concentration in approximately 1–2 hours. The absorption
of ropinirole is not affected by food; however, when
ropinirole is taken with a high-fat meal, its Tmax is increased
by 2.5 hours and its Cmax is decreased by approximately
25%. In clinical studies, over 88% of a radiolabeled dose
was recovered in urine and the absolute bioavailability was
55%, indicating a first-pass effect. The clearance of
ropinirole after oral administration to patients is 47 L/hour
and its elimination half-life is approximately 6 hours. It is
extensively metabolized by the liver to inactive metabolites
and demonstrates linear kinetics over the therapeutic dosing
range of 1–8 mg 3 times daily. The major cytochrome P450
isozyme involved in ropinirole metabolism is CYP1A2, and
inhibitors or inducers of this enzyme have been shown to
alter its clearance when coadministered with ropinirole.
Steady-state concentrations are expected to be achieved
within 2 days of dosing, and it is up to 40% bound to plasma
proteins. Less than 10% of the administered dose is excreted
as unchanged drug in urine. Although there are no gender
effects on oral clearance, it is reduced by 30% in patients
above 65 years compared to younger patients. Based on
population pharmacokinetic analysis, the pharmacokinetics
of ropinirole appear to be unchanged in patients with
moderate renal impairment compared to an age-matched
population. The pharmacokinetics of ropinirole have not
been studied in patients with hepatic impairment.
Clinical efficacy in RLS
Ropinirole as a treatment for RLS was evaluated in 8 open-
label trials and 11 randomized controlled trials between 1998
and 2006.
Open-label trials
There were four open-label clinical series examining the
effects of ropinirole on RLS patients that were published in
1998 and 1999 (Estivill and de la Fuente 1999a; Estivill
and de la Fuente 1999b; Galvez-Jimenez and Khan 1999;
Ondo 1999). These involved small sample sizes of 5–16
subjects and varied in both the dose range of ropinirole
(0.25–4 mg) and duration of treatment (1–10 months).
Significant reductions in the subjective assessment of RLS
symptom severity while on treatment were observed in all
four studies. In the study by Ondo (1999), IRLS Rating Scale
scores significantly improved from 18.6±2.4 to 7.7±3.5,
which is a robust finding given that the population was
difficult to treat since the patients used an average total
number of 4.2±1.8 medications for their RLS symptoms
prior to entering the study and many had levodopa-induced
RLS rebound during the study. In one of the studies by
Estivill and de la Fuente (1999b), significant improvement
in the objective polysomnographic variables of sleep
efficiency, total sleep time, and periodic limb movements
were observed as well as subjective improvement in RLS
symptoms, not only soon after the initiation of ropinirole
treatment but also following a month of treatment.
Table 1 General therapeutic guidelines for restless legs syndrome (RLS)
1. Consider discontinuing substances and medications that may potentially worsen RLS (caffeine, alcohol, nicotine, dopamine antagonists,
tricyclic and selective serotonin release inhibitor [SSRI] antidepressants, lithium, first-generation antihistamines, beta-blockers).
2. Discuss good sleep hygiene practices (eg, standardizing sleep-wake schedules, bright light therapy) as an adjunct to pharmacotherapy.
3. Since treatment is symptomatic and not curative, discuss the possibility that the patient may need to take the medication indefinitely.
4. Dosage, timing, frequency, and side effect profiles (especially augmentation and rebound) of the medication should be carefully considered.
5. Age, severity/frequency of symptoms, and the impact of RLS on the patient’s life are important considerations in the selection and timing of
administration of the RLS medications.
6. A given medication should be started at the lowest possible dose and then slowly and carefully increased to its lowest effective dose based
on titration instructions or schedules provided to the patient. The patient should be instructed to discontinue the medication and contact
his or her physician with the appearance of any adverse effects.
7. Medication should be started in the early evening or bedtime; however, the patient should be given some latitude in the dosage and timing of
his or her medication to adjust for the appearance of symptoms.
8. Combination therapy (eg, combining medications of several different classes) should be considered for patients who fail to respond to
individual RLS medications.Neuropsychiatric Disease and Treatment 2006:2(4) 411
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Two other open-label clinical series were conducted to
assess the long-term safety and tolerability of ropinirole in
RLS (Bogan et al 2005b; Dreykluft et al 2005; Garcia-
Borreguero et al 2005c); they were multi-center, 52-week
trials, one conducted in the US and the other in Europe.
Otherwise, the designs of these two trials were similar;
patients were eligible for the trials if they had successfully
completed a previous trial of ropinirole in RLS, and the
ropinirole dose levels were titrated for efficacy, 0.5–4.0 mg/
day. A total of 251/310 and 60/81 patients completed the
two studies; the efficacy analyses included 308 and 81
patients (receiving a mean dose of 1.6 and 1.7 mg/day of
ropinirole, respectively) and safety analyses included 309
and 81 patients, respectively. Rapid and extensive
improvements in IRLS Rating Scale total scores were
observed and were maintained throughout the studies, with
mean baseline scores of 22.0 and 22.7 reduced to 10.9 and
9.8, respectively, at week 52 last observation carried forward
(LOCF). Greater than 74% of patients were much or very
much improved on the Clinical Global Impression-
Improvement (CGI-I) Scale at week 52 LOCF compared
with baseline, and sleep parameters as well as quality of
life measures were improved. Combining the two studies,
the most commonly reported adverse events (≥10%) were
nausea, headache, and arthralgia, and the majority of the
adverse events were mild to moderate in intensity, with the
first occurrence largely in the initial 12 weeks of therapy.
There were few reports of augmentation (3.9%), which is a
known side-effect of dopaminergic agents and is a
paradoxical increase in RLS symptom severity despite
increased dose. This phenomenon manifests as worsened
symptoms, spread of symptoms to other limbs, and/or
symptom occurrence earlier in the day.
Two head-to-head, open-label comparisons of RLS
treatments were conducted: ropinirole vs gabapentin and
ropinirole vs levodopa sustained-release (SR). In the first
randomized, 4-week, open-label trial, 8 patients received
gabapentin (starting at 300 mg, titrated to symptom relief;
mean dose, 800±397 mg) and 8 patients received ropinirole
(starting at 0.5 mg, titrated to symptom relief; mean dose,
0.78±0.47 mg) (Happe et al 2003). Both IRLS Rating Scale
severity and PLMS by polysomnography were significantly
improved and, in the majority of patients, RLS symptoms
were still improved after 6–10 months of follow-up. The
second head-to-head study was a 14-week, open-label,
randomized, crossover trial (6 weeks of first treatment
condition, 1 washout week, 6 weeks of second treatment
condition) comparing ropinirole vs levodopa SR in 11 RLS
patients on chronic hemodialysis (Pellecchia et al 2004).
Ropinirole was observed to be superior to levodopa SR in
improving RLS severity (IRLS Rating Scale and CGI Scale)
and sleep time; the authors concluded that ropinirole is more
effective than levodopa SR in the treatment of RLS in
patients on chronic hemodialysis.
Randomized controlled trials (Table 2)
The first controlled trial was published by Saletu et al 2000
(Saletu et al 2000a, 2000b); these investigators conducted
a single-blinded, non-randomized, placebo-controlled,
crossover trial investigating the acute effects of ropinirole
on 12 patients diagnosed with RLS. In addition to self-rating
and visual analog scales, polysomnography and a
psychometric test battery were used to objectively assess
sleep, cognition, mood, and periodic limb movements.
Compared with placebo, ropinirole significantly improved
subjective and objective measures of sleep quality, fine
motor activity, reaction time, and PLMS per hour of sleep.
Adler and colleagues conducted a double-blind, placebo
controlled, crossover study of ropinirole in 22 patients with
RLS (Adler et al 2004). Patients were treated with either
ropinirole (0.5–6 mg/day for 4 weeks, had a 1-week
washout, and then crossed-over to the other arm for 4 weeks.
There was a significant improvement in the IRLS Rating
Scale from 25±7 during placebo treatment to 13±12 during
ropinirole treatment. Eight of the 22 patients had complete
resolution of their RLS symptoms during the ropinirole
treatment. As an additional efficacy measure, global change
scores (–3 markedly worse to +3 markedly improved) were
significantly higher at the end of ropinirole vs placebo
treatment. The most common adverse events for the
ropinirole group vs the placebo group were nausea (27.3 vs
4.5%) and dizziness (22.7 vs 0%). The mean daily dose
was 4.6±2.0 mg/day, with 14 out of 22 patients receiving
the full 6 mg/day, which was a relatively high ropinirole
dose; however, the patients tolerated this dose well with
only one patient prematurely discontinuing ropinirole
treatment due to adverse events (dizziness, nausea, and
vomiting).
Trenkwalder and colleagues conducted a study named
TREAT RLS 1, a 12-week, multi-center, double-blind,
randomized, placebo-controlled trial involving 284 RLS
patients from 10 European countries (Trenkwalder et al
2004). Patients were randomized (1:1) to receive either
ropinirole 0.25–4.0 mg once daily or placebo. SignificantNeuropsychiatric Disease and Treatment 2006:2(4) 412
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improvement in the IRLS Rating Scale (primary efficacy
endpoint) at a mean ropinirole dose of 1.90±1.13 mg/day at
week 12 was found compared with placebo, and significantly
more patients in the ropinirole group (53.4%) showed
improvement in the CGI-I Scale at week 12 compared with
the placebo group (40.9%). The clinical benefit of ropinirole
was evident by week 1 as reflected by significant differences
in both the IRLS Rating Scale and CGI Scale, and the most
common adverse events for the ropinirole group vs the
placebo group were nausea (37.7 vs 6.5%) and headache
(19.9 vs 16.7%). Ropinirole was effective despite the
presence of a placebo effect that the authors concede “was
larger than expected;” the IRLS Rating Scale total score at
week 12 was 13.5±9.3 for the ropinirole group and 17.1±9.4
for the placebo group. However, the authors point out that
similar placebo effects are common in trials in other diseases
in which subjective tools are used to assess efficacy and
that patients may have had enhanced treatment expectations
due to such reasons as the poorly recognized status of RLS.
A companion study to the TREAT RLS 1 study was the
TREAT RLS 2 study conducted by Walters and colleagues
(Walters et al 2004). The same experimental design and
endpoints were used in both studies, with a total of 267
RLS patients participating in this study. The mean (±standard
error) adjusted IRLS Rating Scale score change between
baseline and week 12 was significantly greater for patients
receiving ropinirole (–11.2±0.76) than for those receiving
placebo (–8.7±0.75). Significantly more patients in the
ropinirole group responded as “much” or “very much”
improved on the CGI-I Scale compared with those in the
placebo group (59.5 vs 39.6%, respectively) at week 12.
Significant improvements in the IRLS Rating Scale and
CGI-I Scale scores were also found at week 1. Patients also
showed significant improvement in all four domains of the
Medical Outcomes Study (MOS) sleep scale, the overall
life-impact score on the RLS Quality of Life (QoL)
questionnaire, and three of the eight domains of the MOS
Short Form (SF)-36 Health Survey. The two most common
severe adverse events reported in >2% of the patients were
nausea (8 patients receiving ropinirole, none receiving
placebo) and headache (5 patients in each group); adverse
events led to the discontinuation of <10% of patients in each
treatment group. Similar to the TREAT RLS 1 study, a large
placebo effect that lessened the treatment difference was
observed in this study; however, the same explanations used
to account for this effect in the former study is applicable to
this study as well. The authors also point out that the single-
dosing schedule at 1–3 hours before bedtime may have
lessened the relative treatment effect of ropinirole,
particularly for severely affected patients who had symptom
onset before dosing. Although a more flexible dosing
schedule would have undoubtedly enhanced the difference
in treatment groups, the beneficial effects of ropinirole were
documented across several measures of efficacy, sleep
parameters, and quality of life in these two large-scale
companion studies.
A 12-week, multi-center, double-blind, randomized,
placebo-controlled trial was conducted by Allen and
colleagues, in which they assessed 65 patients with both
RLS and PLMS (Allen et al 2004a). Patients received
flexible dosing of ropinirole (0.25–4 mg/day) and placebo
that occurred once daily near bedtime. The PLMS per hour
were significantly decreased for patients receiving ropinirole
(48.5–11.8) at a mean dose of 1.8 mg/day vs those receiving
placebo (35.7–34.2). PLMS with arousals per hour and
PLMW per hour similarly significantly decreased for those
receiving ropinirole; these measures increased for those
receiving placebo. Sleep adequacy by the MOS sleep scale
was significantly improved with ropinirole treatment, and
significantly increased stage 2 sleep amounts and the
patient’s ability to initiate sleep compared to placebo were
observed; however, a significantly greater increase in stages
3 and 4 sleep was observed in the placebo group. The authors
posit that since PLMS mainly disrupt stage 2 sleep, effective
treatment of RLS may be expected to increase stage 2 sleep,
and that sleep deprivation over several nights results in an
increased drive for sleep, expressed by the increased stages
3 and 4 sleep. The most common adverse effects reported
during treatment were headache (34.4%) and nausea
(31.3%).
Two randomized, placebo-controlled, forced-titration
studies, primarily to assess the pharmacokinetics, safety, and
tolerability of ropinirole, were conducted. The studies
randomized RLS patients in a 2:1 ratio to ropinirole at a
dose range of 0.25–4.0 mg/day over 7 weeks (maximum
dose dependent on tolerability) or placebo. In the first study
(ropinirole, 18 patients; placebo, 10 patients) (Allen et al
2004b; Kelly and Mistry 2004; Tompson and Della Pasqua
2004), based on a logistic model and factoring
pharmacokinetic variability, 50% of patients were predicted
to respond on either IRLS Rating Scale score or PLMS/hr
at doses of ropinirole >1.5 mg/day. Ropinirole produced a
greater reduction in PLMS/hr by actigraphy compared with
placebo, particularly in the first third of the night when the
PLMS were observed to be most prevalent. In the second
study (ropinirole, 37 patients; placebo, 17 patients) (KellyNeuropsychiatric Disease and Treatment 2006:2(4) 414
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and Mistry 2005), 29 (78.4%) of the ropinirole-treated
patients completed the study, at least 70% of the patients
tolerated each ropinirole dose, and 16 (43.2%) tolerated the
highest dose of 4.0 mg. The two most frequently reported
adverse events were nausea (59.5%) and headache (43.2%);
the majority of the 237 adverse events reported in 35 patients
receiving ropinirole (compared to 39 adverse events reported
in 13 patients receiving placebo) were mild or moderate in
intensity (224/237, 94.5%) and there were no unexpected
or serious adverse events. As expected with a forced-titration
regimen, the incidence of adverse events was high, but the
high percentage of patients tolerating each ropinirole dose
level and the improvement in RLS and PLMS suggest that
this dosing regimen is generally well tolerated and effective
in these patients.
Bliwise and colleagues (2005) conducted a short-term
(2-week), double-blind, randomized, placebo-controlled
trial on 22 RLS patients (ropinirole, 9; placebo, 13) who
had long-standing RLS (mean duration of symptoms, 26.1
years) and had successfully undergone 4 weeks of open-
label titration and dose adjustments with ropinirole for RLS
symptoms. At a mean dose of 1.4 mg, ropinirole significantly
decreased RLS severity and PLMS without changing sleep
parameters.
An international, multi-center study evaluated 106 out
of a total of 202 RLS patients aged 18–49 years who received
24 weeks of ropinirole at a dose range of 0.25–4.0 mg/day
in a single-blind fashion (Haan et al 2004; Karrasch et al
2004; Montplaisir et al 2004a, 2004b). At the end of this
single-blind phase, 92 patients meeting criteria for treatment
continuation were randomized to 12 weeks of double-blind
treatment with either ropinirole or placebo. The primary
endpoint was the proportion of patients relapsing (IRLS
Rating Scale score of ≥15 that had worsened by at least 6
points compared to the start of double-blind treatment or
withdrawal due to lack of efficacy) during the double-blind
phase. The odds of a patient relapsing while on placebo
were three times greater than those of a patient receiving
ropinirole. During the double-blind phase, significant
improvements were found in those receiving ropinirole
compared to those receiving placebo in quality of life and
four domains of the SF-36; patients switching to placebo
during the double-blind phase experienced significant
worsening in sleep disturbance, daytime somnolence, and
sleep quality of the MOS sleep scale. Most of the adverse
events were mild or moderate in severity, and nausea and
headache were the most common adverse events. Three
patients (1.5%) experienced augmentation (reported as
hyperkinesias) during ropinirole treatment, but it
subsequently and spontaneous resolved with continued
ropinirole treatment (Karrasch et al 2004).
Bogan and colleagues conducted a 12-week, multi-
center, double-blind, randomized, placebo-controlled trial
called TREAT RLS US in 308 patients aged 18–79 years
with RLS (Bogan et al 2006). Patients received flexible
dosing of ropinirole (0.25–4 mg/day) and placebo that
occurred once daily 1–3 hours before bedtime. At week 12
LOCF, the mean IRLS Rating Scale total score in the
ropinirole group had significantly decreased from 22.0±4.99
at baseline to 8.4±7.32 compared with a reduction in the
placebo group from 21.6±4.79 to 11.9±9.20. Significantly
more patients in the ropinirole group were rated as
responders (much or very much improved) on the CGI-I
Scale at week 12 LOCF compared with those receiving
placebo. Similar significant findings in IRLS Rating Scale
and CGI-I Scale scores were found at week 1 LOCF. A post-
hoc analysis showed that there was a significant
improvement in IRLS Rating Scale score from baseline to
day 3 OC (observed case); indicating that the effect of
ropinirole on RLS may be as early as 72 hours after
administration (Bogan et al 2005a). Ropinirole significantly
improved IRLS Rating Scale scores at every subsequent
measurement starting at day 3 through week 12 (Sethi and
Carson 2005). Significant improvement in subjective
measures of sleep (disturbance, quantity, and adequacy),
quality of life, and anxiety were observed in the ropinirole
group. The PLMs index as measured by actigraphy was
significantly decreased from baseline to week 6 in 110
patients in the ropinirole group compared to 113 patients in
the placebo group (Rye et al 2005). The two most common
adverse events that were reported in at least 5% of patients
were nausea and headache.
A 12-week, multi-center, double-blind, randomized,
placebo-controlled, flexible-dose study was conducted to
investigate the efficacy of ropinirole in RLS patients
requiring extended treatment coverage (Kushida and Tolson
2006). Patients received ropinirole (0.5–6.0 mg/day) in
divided doses, with the first dose taken 1 hour before their
usual onset of symptoms and the second dose 3–8 hours
after the first dose. A total of 363 patients were randomized,
with 359 patients comprising the intention-to-treat
population. At week 12 LOCF, the mean total daily dose
was 3.1±1.97 mg for ropinirole and, compared with placebo,
the improvement from baseline in IRLS Rating Scale total
score was significantly greater for ropinirole and more
ropinirole-treated patients were classified as responders.Neuropsychiatric Disease and Treatment 2006:2(4) 415
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These results prompted the investigators to conclude that
ropinirole is an effective treatment for RLS patients
requiring extended treatment coverage.
Expert opinion
The eleven controlled trials in the preceding section had
sample sizes from 12 to 363 subjects, lasted from 4 to 36
weeks in duration, consisted of both parallel and crossover
designs, and included one with an open-label period (Table
2). The strengths of the later trials were that they used several
validated, independent instruments to assess RLS symptoms
and severity (eg, RLSQ, IRLS Rating Scale, CGI-I Scale)
and for the most part had large sample sizes and longer
treatment periods.
Several conclusions could be reached upon review of
these studies and by post-hoc analyses conducted on a
combination of the data from some of the above studies:
1. Ropinirole effectively treats the RLS symptoms and the
major consequences associated with RLS. Specifically,
it is highly effective in improving the symptoms of RLS,
the sleep disturbance likely resulting from the symptoms,
and the quality of life of RLS patients (Ferini-Strambi
et al 2004). Ropinirole is also effective in controlling
PLMS, which are frequently associated with RLS.
2. The onset of action of ropinirole treatment is rapid. Even
at low doses (0.25–0.5 mg/day) during the first week of
treatment, ropinirole was effective in significantly
reducing the severity of RLS (Becker et al 2004; Allen
et al 2005a). RLS symptom improvement may be seen
after as few as 2 nights of ropinirole treatment (Ziman
et al 2006b).
3. An initial response to ropinirole occurred in some patients
at 0.25 mg/day; however, by week 12, a considerable
proportion of patients benefited from titration to higher
doses that were both efficacious and tolerable (ie, most
patients titrated to and responded at a mean dose of up
to approximately 2 mg/day) (Garcia-Borreguero et al
2005a, 2005b).
4. The benefits of ropinirole appear to be maintained in the
long-term (Ferini-Strambi et al 2004; Tidswell et al
2004). Two open-label clinical series each lasting 52
weeks showed continued efficacy of ropinirole in
reducing RLS severity.
5. Similar clinical responses to ropinirole are observed for
both early- and late-onset (over age 45 years) RLS
phenotypes (see section on Phenotypes and genotypes).
Allen and colleagues suggest that the two phenotypes
involving different biological processes may have a
common final expression of dopaminergic pathology
responsive to ropinirole (Allen et al 2005b; Sethi and
Hosford 2006).
6. Ropinirole is effective in controlling both evening and
nighttime RLS symptoms (Lee and Earl 2006).
7. Subjective sleep quality and quantity as well as objective
RLS motor symptoms are significantly improved by
ropinirole; the subjectively experienced improvements
in sleep with ropinirole may be mediated via
improvements in the underlying RLS-associated motor
symptoms (Allen et al 2004d, 2004c). Reduced daytime
alertness, a consequence of chronic sleep disruption, may
improve in RLS patients with moderate-to-severe RLS
receiving ropinirole (Lee et al 2006).
8. Ropinirole treatment produced greater improvements in
mood symptoms in patients with RLS compared to those
on placebo. Mood was assessed by the Hospital Anxiety
and Depression Scale (HADS), the Profile of Mood
States (POMS), and item 10 of the IRLS Rating Scale
(related to mood symptoms) (Thomas et al 2006).
9. Ropinirole is well tolerated with adverse events generally
mild or moderate. The side effect profile of ropinirole is
comparable to other non-ergoline derivatives, with the
main side effects related to its dopaminergic activity.
Nausea, dizziness, headache, and somnolence are the
common side-effects reported in the clinical trials of
ropinirole. From data from 616 patients (ropinirole, 309;
placebo, 307), the most common adverse event was
nausea (ropinirole, 37.9%; placebo, 8.1%) and most of
the patients reported the nausea to be mild or moderate
(ropinirole, 85%; placebo, 100%). The overall
withdrawal rates were low (ropinirole, 2.3%; placebo,
0.3%), indicating that these events did not limit
treatment. Most adverse events occurred first in the initial
2-week interval of the study and ongoing decreases in
incidence were observed in the subsequent 2-week
intervals (ie, maintenance stages of the studies)
(Montagna et al 2004). Augmentation and tolerance
commonly occur with dopaminergic treatment of RLS,
but are reported at a lower frequency in studies with
ropinirole compared to those with levodopa. A possible
association of dopaminergic agonists and pathologic
gambling has been reported in patients with Parkinson’s
disease (PD); however, further study is warranted to
study this phenomenon and to determine if it is a side
effect of dopamine agonists or a symptom of advanced
PD (Driver-Dunckley et al 2003; Dodd et al 2005).
Similarly, daytime sleepiness to the level of “sleepNeuropsychiatric Disease and Treatment 2006:2(4) 416
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attacks” has been reported in conjunction with
automobile accidents in PD patients taking dopamine
agonists (Frucht et al 1999; Ondo et al 2001; Pal et al
2001). In RLS patients, Bassetti reported a single case
of an RLS patient with multiple sleep attacks while taking
pergolide at a dose of 0.25 mg/day (Bassetti et al 2002);
there appears to be no report of sleep attacks in RLS
patients taking non-ergoline dopamine agonists.
Although dopamine agonists have been associated with
sleep attacks, there is no consensus on whether a causal
relationship exists (Plowman et al 2005); this
phenomenon may be apparent more in PD patients due
to the tendency towards daytime sleepiness in PD
patients independent of treatment (Rye et al 2000) and
the higher doses of dopaminergic agents needed to
control PD compared with RLS.
10. The safety of ropinirole is not established in pediatric
patients, so children should be considered for treatment
only if there is significant impairment of their daytime
alertness levels, cognition, school performance, behavior
(eg, moodiness or irritability due to drowsiness), and/or
quality-of-life. There are no studies of ropinirole in
human pregnancy; it is classified as a pregnancy category
C drug. A pregnant woman with RLS should definitely
be informed that her RLS symptoms will typically
resolve within one month of delivery.
Recommendations
Indications of use
Ropinirole is effective in treating RLS as well as PLMS.
Treatment with ropinirole should be considered even in RLS
patients who have failed other therapies, since it has been
shown to be effective in improving RLS symptoms in this
subgroup of patients (Ziman et al 2006a).
Dosing
It is important to take ropinirole prior to symptom onset,
since the action of dopamine agonists generally starts 90–
120 minutes after ingestion (Silber et al 2004). Further, for
daily RLS, ropinirole may be started at 0.25 mg per day at 2
hours before RLS symptom onset, and then increased by
0.25 mg every 2 to 3 days until symptom relief is achieved
(Silber et al 2004). Starting dose should be individualized
based on RLS severity and age. In general, the effective
dose for ropinirole is typically 2 mg or less, although some
patients may require doses as high as 6 mg/day.
Adverse events
The common side-effects of nausea, dizziness, headache,
and somnolence are typically worse in the first two weeks
of treatment and may require dose reduction but rarely
discontinuation of drug. The patient should be warned and
monitored for sleep attacks; the presence of this adverse
event should warrant immediate reduction or discontinuation
of the drug. The probability of developing augmentation or
tolerance is low; if they occur, decreasing or stopping this
medication, or switching to another medication, may be
necessary.
In conclusion, ropinirole is effective and well tolerated
in the treatment of patients with RLS; it has rapid onset of
action and long-term benefit with adverse events in the mild
to moderate range.
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